

RMB creates a unique pharma solution to enable disposal of Adcock Ingram's front ended formulations business in India

RMB is proud to have advised Adcock Ingram Holdings Limited, South Africa's leading pharmaceutical company on the disposal of its Indian front ended formulations business ("Adcock India") through a management buy-in by Oaknet Lifesciences, a start-up pharmaceutical company owned by industry experts, supported by Samara Capital, a leading India-focused private equity fund. RMB played an instrumental role in finding a suitable buyer consortium and delivering a transaction that helped Adcock Ingram achieve its strategic objectives. This INR192crore transaction endorses our capabilities in the healthcare sector and our ability to deliver investment banking solutions to client not only in India but also in the Indo-Africa corridor.

